218 related articles for article (PubMed ID: 33030432)
1. Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis.
Miyata Y; Inoue H; Homma T; Tanaka A; Sagara H
J Investig Allergol Clin Immunol; 2021 Jul; 31(4):346-348. PubMed ID: 33030432
[No Abstract] [Full Text] [Related]
2. Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.
Takenaka K; Minami T; Yoshihashi Y; Hirata S; Kimura Y; Kono H
Allergol Int; 2019 Oct; 68(4):539-540. PubMed ID: 31080020
[No Abstract] [Full Text] [Related]
3. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab.
Chica-Guzmán MV; Morillo-Guerrero R; Carrón-Herrero A; González-de-Olano D; Almonacid-Sánchez C
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):228-230. PubMed ID: 32407950
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
[TBL] [Abstract][Full Text] [Related]
5. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
6. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients.
Kitamura N; Hamaguchi M; Nishihara M; Ikumi N; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Oshima M; Asatani S; Kobayashi H; Takei M
Allergol Int; 2021 Jan; 70(1):148-149. PubMed ID: 32967778
[No Abstract] [Full Text] [Related]
7. Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis.
Kolios AGA; Lutterotti A; Kulcsar Z; Renner T; Rudiger A; Nilsson J
Clin Immunol; 2021 Jan; 222():108574. PubMed ID: 32805452
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
9. Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Colantuono S; Pellicano C; Leodori G; Cilia F; Francone M; Visentini M
Allergol Int; 2020 Jul; 69(3):483-484. PubMed ID: 32224025
[No Abstract] [Full Text] [Related]
10. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
12. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
[TBL] [Abstract][Full Text] [Related]
13. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
15. [SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].
Sugiyama T; Yoshida S; Kikuchi S; Iino Y
Arerugi; 2022; 71(3):242-247. PubMed ID: 35569946
[TBL] [Abstract][Full Text] [Related]
16. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
Pradhan RR; Nepal G; Mandal S
Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
[TBL] [Abstract][Full Text] [Related]
19. Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).
Bandla M; Howard M; McNally A; Armstrong D; Simpson I; Mar A
Australas J Dermatol; 2023 Aug; 64(3):404-407. PubMed ID: 37195732
[TBL] [Abstract][Full Text] [Related]
20. Benralizumab: First Global Approval.
Markham A
Drugs; 2018 Mar; 78(4):505-511. PubMed ID: 29464664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
